CliffBio
small molecule

MOZOBIL

PLERIXAFOR

Loss of exclusivity—loss of exclusivity
CompanyGenzyme →See this company's full patent-cliff portfolio

Drug detail

Brand nameMOZOBIL
Active ingredientPLERIXAFOR
Strength24MG/1.2ML (20MG/ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalDecember 2008
Marketing statusRX

More from Genzyme

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.